Analyst, Leerink Partners
Appears in 3 stories
Last updated Nov 15, 2026
Covering Pfizer
Pfizer has agreed to let Blackstone Life Sciences pay up to $1.5 billion of the development costs for berobenatide, an experimental weight-loss drug injected once a month. The money covers as many as 10 Phase 3 trials through 2028. Pfizer keeps full control of the program and gives up no ownership of the drug.
Updated 7 days ago
Called the results 'mixed'
Bristol Myers Squibb's experimental lung disease drug admilparant met its main goal in a Phase 3 trial, but only at the lower of two tested doses. The 60 milligram dose slowed lung function decline in patients with idiopathic pulmonary fibrosis, while the 120 milligram dose fell short of statistical significance.
Updated Oct 29
As of October 2026: Views approval chances as intact despite two misses
Vaxcyte said Monday its experimental pneumococcal vaccine met every primary goal in the first of three late-stage trials. VAX-31, which targets 31 strains of the bacteria behind pneumonia and meningitis, matched Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all shared strains, beat both on three strains only it covers, and sent shares up roughly 50% to push the company's market value past $12 billion.
Updated Oct 7
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?